Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 87.69M | 84.82M | 65.27M | 34.90M | 20.75M |
Gross Profit | 72.43M | 73.40M | 57.70M | 32.38M | 18.55M |
EBITDA | -30.67M | -24.94M | -94.73M | -54.49M | -119.54M |
Net Income | -29.67M | -21.43M | -96.33M | -56.34M | -118.34M |
Balance Sheet | |||||
Total Assets | 119.90M | 127.87M | 141.46M | 212.78M | 132.05M |
Cash, Cash Equivalents and Short-Term Investments | 67.23M | 78.64M | 105.76M | 181.56M | 114.63M |
Total Debt | 820.00K | 1.42M | 1.77M | 3.63M | 3.98M |
Total Liabilities | 27.90M | 26.88M | 32.23M | 32.68M | 26.21M |
Stockholders Equity | 92.00M | 100.98M | 109.22M | 180.11M | 105.84M |
Cash Flow | |||||
Free Cash Flow | -15.71M | -27.23M | -75.92M | -103.52M | -91.41M |
Operating Cash Flow | -15.71M | -27.23M | -75.92M | -102.56M | -91.23M |
Investing Cash Flow | 0.00 | 0.00 | 0.00 | 61.04M | -2.79M |
Financing Cash Flow | 4.31M | 100.00K | 84.00K | 108.31M | 2.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $204.11M | 122.96 | 2.17% | ― | 134.52% | ― | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
51 Neutral | $230.65M | ― | -52.76% | ― | -70.31% | -11.68% | |
46 Neutral | $218.19M | ― | -32.97% | ― | ― | ― | |
44 Neutral | $217.87M | ― | -29.93% | ― | 3.38% | -36.40% | |
40 Underperform | $223.82M | ― | 87.26% | ― | ― | -43.76% | |
39 Underperform | $230.51M | ― | -75.60% | ― | ― | -2.29% |
Y-mAbs Therapeutics, Inc. has released a corporate overview presentation on its investor relations website, which includes updates on its business operations, clinical trials, and development pipeline. This presentation is intended for investor meetings and a podium presentation at the J.P. Morgan Healthcare Conference, indicating the company’s ongoing engagement with investors and stakeholders in the biopharmaceutical industry.